Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors
NCT03509012 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 105
Last updated 2025-01-14
Summary
This is an open-label, multicenter, phase I study to evaluate the safety and tolerability of durvalumab ± tremelimumab in combination with chemoradiation in patients with advanced solid tumors
Conditions
- Carcinoma, Squamous Cell of Head and Neck
- Carcinoma, Non-Small-Cell Lung
- Small Cell Lung Carcinoma
Interventions
- DRUG
-
IV (intravenous)
- DRUG
-
Tremelimumab
IV
- DRUG
-
Cisplatin (dose level 4)
IV
- DRUG
-
Cisplatin (dose level 3)
IV
- DRUG
-
Carboplatin (dose level 1)
IV
- DRUG
-
Carboplatin (dose level 2)
IV
- DRUG
-
Etoposide (dose level 1)
IV
- DRUG
-
Etoposide (dose level 2)
IV
- DRUG
-
IV
- DRUG
-
Pemetrexed
IV
- RADIATION
-
External beam radiation (dose level 1)
radiation therapy
- RADIATION
-
External beam radiation (dose level 2)
radiation therapy
- RADIATION
-
External beam radiation (hyperfractionated)
radiation therapy
- DRUG
-
Cisplatin (dose level 1)
IV
- DRUG
-
Cisplatin (dose level 2)
IV
- RADIATION
-
External beam radiation (standard)
radiation therapy
Sponsors & Collaborators
- lead INDUSTRY
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 110 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-05-02
- Primary Completion
- 2020-12-31
- Completion
- 2025-01-08
- FDA Drug
- Yes
Countries
- United States
- Japan
- South Korea
- Spain
- Taiwan
Study Locations
More Related Trials
-
An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies
NCT02712905 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.
NCT03983954 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN
NCT04317105 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer
NCT03421353 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Safety, Tolerability of DN1508052-01 in Advanced Solid Tumors
NCT03934359 ·Status: COMPLETED ·Phase: PHASE1
-
Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies
NCT03317496 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors
NCT05901285 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment
NCT04338269 ·Status: TERMINATED ·Phase: PHASE3
-
A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
NCT03768063 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors
NCT03264066 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
NCT05083481 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of QLS31905 Combination Chemotherapy as First-Line Treatment in Patients With Advanced Solid Tumors
NCT06041035 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Clinical Trial to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors
NCT06293651 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
NCT05533697 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
NCT04306900 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients
NCT01974258 ·Status: WITHDRAWN ·Phase: PHASE1
-
A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors
NCT02650713 ·Status: COMPLETED ·Phase: PHASE1
-
Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations
NCT03842228 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced Tumors
NCT03995472 ·Status: COMPLETED ·Phase: PHASE1
-
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
NCT06219941 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract
NCT02928406 ·Status: COMPLETED ·Phase: PHASE3
-
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
NCT00004241 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors
NCT02900157 ·Status: COMPLETED ·Phase: PHASE1
-
Combination Chemotherapy in Treating Patients With Metastatic Solid Tumors
NCT00003711 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
NCT03997968 ·Status: COMPLETED ·Phase: PHASE1/PHASE2